News & Press Releases
Filter by:
Mintz advised the underwriters in connection with Avalo Therapeutics’ $431.3 million public offering of common stock and pre-funded warrants.
Mintz advised the underwriters in connection with InflaRx’s $150 million underwritten offering of ordinary shares.
Mintz advised Axoft, a neurotechnology company, on a $55 million Series A financing round. The funding will be used to expand Axoft’s clinical trials globally and progress US regulatory approval for its implantable Brain-Computer Interfaces (iBCIs).
Mintz Guides Potentia on Closing of Landmark $65 Billion Technology Infrastructure Development in Indiana
April 30, 2026
Mintz advised Potentia Inc. (Potentia), a leading developer of large-scale technology and energy infrastructure, on the closing today of its investment in Heartland Industrial Park, a major technology infrastructure development located in Sullivan County, Indiana.
Supreme Court Questions How Far Generics Makers Can Go When Marketing 'Skinny Label' Drugs
April 30, 2026
Sige Gutman, Chair of Mintz’s Life Sciences Litigation Practice, was quoted in an Endpoints News article examining Supreme Court oral arguments on the limits of “skinny label” drug marketing and potential patent infringement liability for generic manufacturers.
Mintz has been recognized by US News & World Report as a 2026 Best Company to Work For among US law firms, marking the third consecutive year the firm has earned this distinction.
